Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.
作者信息
Merker Vanessa L, Gross Andrea M, Widemann Brigitte C, Plotkin Scott R
机构信息
Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
出版信息
Clin Trials. 2024 Feb;21(1):3-5. doi: 10.1177/17407745231201345. Epub 2023 Sep 29.
Abstract
摘要
相似文献
1
Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.
Clin Trials. 2024 Feb;21(1):3-5. doi: 10.1177/17407745231201345. Epub 2023 Sep 29.
2
Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.
Clin Trials. 2024 Feb;21(1):40-50. doi: 10.1177/17407745231203330. Epub 2023 Oct 31.
3
Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.
Neurology. 2013 Nov 19;81(21 Suppl 1):S6-14. doi: 10.1212/01.wnl.0000435747.02780.bf.
4
Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS.
Neurology. 2021 Aug 17;97(7 Suppl 1):S4-S14. doi: 10.1212/WNL.0000000000012430. Epub 2021 Jul 6.
5
Conclusions and future directions for the REiNS International Collaboration.
Neurology. 2013 Nov 19;81(21 Suppl 1):S41-4. doi: 10.1212/01.wnl.0000435748.79908.c5.
6
Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.
Clin Trials. 2024 Feb;21(1):18-28. doi: 10.1177/17407745231217279. Epub 2024 Feb 6.
7
Achieving consensus for clinical trials: the REiNS International Collaboration.
Neurology. 2013 Nov 19;81(21 Suppl 1):S1-5. doi: 10.1212/01.wnl.0000435743.49414.b6.
8
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Neurology. 2016 Aug 16;87(7 Suppl 1):S31-9. doi: 10.1212/WNL.0000000000002929.
9
From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
Am J Med Genet A. 2019 Jun;179(6):1098-1106. doi: 10.1002/ajmg.a.61112. Epub 2019 Mar 25.
10
Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.
Clin Trials. 2024 Feb;21(1):29-39. doi: 10.1177/17407745231201338. Epub 2023 Sep 29.
本文引用的文献
1
Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.
Clin Trials. 2024 Feb;21(1):18-28. doi: 10.1177/17407745231217279. Epub 2024 Feb 6.
2
Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.
Clin Trials. 2024 Feb;21(1):6-17. doi: 10.1177/17407745231205577. Epub 2023 Dec 23.
3
Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
Clin Trials. 2024 Feb;21(1):73-84. doi: 10.1177/17407745231209224. Epub 2023 Nov 14.
4
Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.
Clin Trials. 2024 Feb;21(1):51-66. doi: 10.1177/17407745231207970. Epub 2023 Nov 8.
5
Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.
Clin Trials. 2024 Feb;21(1):40-50. doi: 10.1177/17407745231203330. Epub 2023 Oct 31.
6
Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.
Clin Trials. 2024 Feb;21(1):29-39. doi: 10.1177/17407745231201338. Epub 2023 Sep 29.
7
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
Clin Trials. 2024 Feb;21(1):67-72. doi: 10.1177/17407745231178839. Epub 2023 Jun 2.
8
FDA regulatory considerations for the review of drugs intended to treat pediatric cancers and rare tumors.
Curr Opin Pediatr. 2023 Feb 1;35(1):48-54. doi: 10.1097/MOP.0000000000001201. Epub 2022 Nov 11.
9
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
Genet Med. 2022 Sep;24(9):1967-1977. doi: 10.1016/j.gim.2022.05.007. Epub 2022 Jun 9.
10
Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS.
Neurology. 2021 Aug 17;97(7 Suppl 1):S4-S14. doi: 10.1212/WNL.0000000000012430. Epub 2021 Jul 6.
Zotero 插件